{"id":139153,"title":"MedPal AI Revenue Surges Above £8.6 Million After Record July","publisher":"Share Talk","author":"sharetalk","published":"2026-08-04T08:04:50+00:00","modified":"2026-08-04T08:04:50+00:00","canonical_url":"https://www.share-talk.com/medpal-ai-revenue-surges-above-8-6-million-after-record-july/","markdown_url":"https://www.share-talk.com/medpal-ai-revenue-surges-above-8-6-million-after-record-july.md","json_url":"https://www.share-talk.com/medpal-ai-revenue-surges-above-8-6-million-after-record-july.json","category":"Health","categories":["Health","Healthcare","Pharmaceutical"],"tags":["blood testing","eMARx","Jason Drummond","Juno","MedPal AI plc","MedPal Health OS","MPAL","NHS pharmacy services"],"featured_image":"https://i0.wp.com/www.share-talk.com/wp-content/uploads/2026/08/91e02005-730f-4964-8468-352e0c83a861.png?fit=1726%2C911&quality=80&ssl=1","format":"news","language":"en-GB","content":"[MedPal AI PLC (AIM: MPAL)](https://www.investegate.co.uk/announcement/rns/medpal-ai-plc--mpal/july-trading-update/9702437) shares rose **19%** after the AI-powered digital health company reported a record July, with all three of its recurring revenue streams contributing to growth for the first time.\n\nThe company said its **annualised recurring revenue run rate has exceeded £8.6 million**, representing growth of more than **70% in just two months** and rising from zero revenue only nine months ago when its dispensing operations launched.\n\nNHS prescription dispensing reached a new monthly record of **47,223 prescription items** in July, an increase of **11.8%** on the previous record set in May. The NHS pharmacy business is now operating at an annualised revenue run rate of more than **£5.5 million**.\n\nThe group’s recently launched **New Health** GLP-1 weight management clinic generated more than **£180,000** of private prescription revenue during July after only three weeks of marketing, equating to an annualised run rate above **£2.2 million**.\n\nMeanwhile, software-as-a-service revenue from **eMARx**, acquired in July, is contributing an annualised **£843,000** of recurring subscription income at an **82% gross margin**.\n\nMedPal highlighted that all three revenue streams are recurring in nature, comprising repeat NHS prescriptions, ongoing private treatment plans and software subscriptions.\n\nThe company also plans to accelerate growth by cross-selling NHS pharmacy services to private healthcare customers while expanding uptake of additional products including at-home blood testing, the **MedPal Health OS** platform and its AI health assistant, **Juno**.\n\nChief executive **Jason Drummond** said the business had grown from zero to **£8.6 million of annualised recurring revenue in just nine months**, adding that the group was “just getting started” as it expands cross-selling and customer monetisation opportunities."}